

UnitedHealthcare Commercial Medical Policy Update Bulletin Quick View: July 2024



A list of recently approved, revised, and/or retired Medical Policies and/or Medical Benefit Drug Policies is provided below for your reference. For a comprehensive summary of the latest updates, refer to the Medical Policy Update Bulletin: July 2024.

Take Note

Quarterly CPT® and HCPCS Code Updates

Effective **Jul. 1, 2024**, all applicable Medical Policies and Medical Benefit Drug Policies have been updated to reflect the quarterly Current Procedural Terminology (CPT®) and Healthcare Common Procedure Coding System (HCPCS) code additions, revisions, and deletions. Refer to the following sources for information on the code updates:

- American Medical Association: Current Procedural Terminology: CPT[®]
- Centers for Medicare & Medicaid Services: Healthcare Common Procedure Coding System (HCPCS) Quarterly Update

Refer to the Medical Policy Update Bulletin: July 2024 for a list of impacted policies and corresponding details.

Medical Policy Updates

Policy Title	Status	Effective Date
Ambulance Services	Updated	Jul. 1, 2024
Chromosome Microarray Testing (Non-Oncology Conditions)	Revised	Aug. 1, 2024
Continuous Glucose Monitoring and Insulin Delivery for Managing Diabetes	Revised	Sep. 1, 2024
Cosmetic and Reconstructive Procedures	Updated	Aug. 1, 2024
Fecal Calprotectin Testing	Retired	Jul. 1, 2024
Genetic Testing for Cardiac Disease	Updated	Jul. 1, 2024
Genetic Testing for Hereditary Cancer	Updated	Jul. 1, 2024
Glaucoma Surgical Treatments	Revised	Aug. 1, 2024
Habilitation and Rehabilitation Therapy (Occupational, Physical, and Speech)	Updated	Jul. 1, 2024
Molecular Oncology Companion Diagnostic Testing	Updated	Jul. 1, 2024
Molecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment Decisions	Updated	Jul. 1, 2024
Occipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache)	Updated	Aug. 1, 2024
Pharmacogenetic Panel Testing	Updated	Jul. 1, 2024
Skin and Soft Tissue Substitutes	Revised	Sep. 1, 2024
Surgery of the Ankle	Revised	Sep. 1, 2024
Surgery of the Foot	Revised	Sep. 1, 2024
Surgery of the Hand or Wrist	Updated	Aug. 1, 2024
Surgery of the Knee	Revised	Sep. 1, 2024
Transarterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT) for the Treatment of Malignant Cancers of the Liver	Revised	Aug. 1, 2024

Policy Title	Status	Effective Date	ı
Whole Exome and Whole Genome Sequencing (Non-Oncology Conditions)	Updated	Jul. 1, 2024	

Medical Benefit Drug Policy Updates

Policy Title	Status	Effective Date
17-Alpha-Hydroxyprogesterone Caproate (Makena® and 17P)	Retired	Jul. 1, 2024
Gene Therapies for Hemophilia B	Revised	Aug. 1, 2024
Infliximab (Avsola®, Inflectra®, Remicade®, & Renflexis®)	Updated	Jul. 1, 2024
Maximum Dosage and Frequency	Revised	Aug. 1, 2024
Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®)	Revised	Aug. 1, 2024
Rituximab (Riabni®, Rituxan®, Ruxience®, & Truxima®)	Revised	Aug. 1, 2024
RNA-Targeted Therapies (Amvuttra® and Onpattro®)	Revised	Aug. 1, 2024
Xolair® (Omalizumab)	Revised	Aug. 1, 2024

General Information

The inclusion of a health service (e.g., test, drug, device, or procedure) in this bulletin indicates only that UnitedHealthcare is adopting a new policy and/or updated, revised, replaced, or retired an existing policy; it does not imply that UnitedHealthcare provides coverage for the health service. Note that most benefit plan documents exclude from benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health care professionals may not seek or collect payment from a member for services not covered by the applicable benefit plan unless first obtaining the member's written consent, acknowledging that the service is not covered by the benefit plan and that they will be billed directly for the service.

Note: The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member's benefit plan and any applicable federal or state regulatory requirements. Additionally, UnitedHealthcare reserves the right to review the clinical evidence supporting the safety and effectiveness of a medical technology prior to rendering a coverage determination.

UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Medical Policy Update Bulletin was developed to share important information regarding changes to our Medical Policies and Medical Benefit Drug Policies. When information in this bulletin conflicts with applicable state and/or federal law, UnitedHealthcare follows such applicable federal and/or state law.

Policy Update Classifications

New

New clinical coverage criteria have been adopted for a health service (e.g., test, drug, device, or procedure)

Updated

An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated

Revised

An existing policy has been reviewed and revisions have been made to the clinical coverage criteria

Replaced

An existing policy has been replaced with a new or different policy

Retired

The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy



The complete library of UnitedHealthcare Medical Policies and Medical Benefit Drug Policies is available at **UHCprovider.com** > Policies and Protocols > Commercial Policies > Medical & Drug Policies.